btk inhibitors: investigating disease relevant mechanisms in multiple sclerosis
Published 2 years ago • 464 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
2:22
btk inhibitors for multiple sclerosis: progressive disease and de-escalation
-
4:22
btk inhibitors in treating the spectrum of ms
-
1:46
potential of btk inhibitors in ms
-
3:41
review of btk inhibition in ms
-
1:50
btk inhibitors for ms treatment: what do the recent trial readouts mean for the field?
-
6:33
updates on btk inhibitor safety in multiple sclerosis
-
48:33
btk inhibitors for ms: progress in the development of an emerging therapeutic approach
-
1:27
btk inhibitors gain ground in ms
-
1:05
ms highlights at aan: btk inhibitors
-
1:15
the safety and efficacy of evobrutinib in multiple sclerosis
-
1:06
clinical trials of btk inhibitors in ms
-
2:22
long-term safety and efficacy of tolebrutinib for relapsing multiple sclerosis
-
58:40
innovations and imaging in ms: examining the evidence, looking toward the future of btk inhibitors
-
3:06
potential of evobrutinib to target progressive ms
-
4:38
an outlook on the future therapeutic landscape of ms
-
2:20
phase iii trials of tolebrutinib in relapsing-remitting and progressive ms
-
1:40
the potential role of btk inhibitors in addressing ms treatment gaps
-
6:06
the road ahead for btk inhibitors in multiple sclerosis
-
1:22
ectrims highlights: ai, btk inhibitors & ebv